Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy

David Bobrowski1 | Reha Kumar1 | Peter E. Wu1,2 | Lauren Lapointe-Shaw1,3

Abstract
Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half-lives, the typical duration used to guide pre-operative medication recommendations.

KEYWORDS
diabetes, euglycemic diabetic ketoacidosis, sodium-glucose cotransporter 2 inhibitors

1 | INTRODUCTION

Current guidelines do not recognize the potential for the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors to persist beyond five half-lives of elimination. The objective of this report is to describe a case of prolonged SGLT2 inhibitor effects and to provide a review of similar cases and outline possible explanatory mechanisms.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as canagliflozin, reduce the reabsorption of filtered glucose at the proximal renal tubules and lower the renal threshold for glucose excretion.1 This inhibition promotes glycosuria, resulting in decreased plasma glucose and increased risks of volume depletion and mycotic urinary tract infections.2 SGLT2 inhibitors may also directly act on pancreatic α-cells to increase plasma glucagon levels.1 These metabolic changes produce a lower insulin-to-glucagon ratio, which can predispose patients to ketoacidosis while maintaining normoglycemia.1 The objective of this report is to describe a case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis (DKA) with prolonged ketosis and glycosuria, and discuss the potential for SGLT2 inhibitor effects to persist well beyond five half-lives of drug elimination.

2 | CASE REPORT

An 81-year-old woman presented to the emergency department (ED) with delirium secondary to dehydration and constipation. She had a past medical history of type 2 diabetes mellitus (T2DM), vascular dementia, stroke in 2017, bioprosthetic aortic valve replacement, multi-vessel coronary bypass surgery, hypertension,
hypercholesterolemia, macular degeneration, and remote cholecystectomy. Medications on presentation are listed in Table 1. Initial investigations in the ED revealed a lactate of 4.7 mmol/L (reference range: 0.5–2.2 mmol/L) and acute kidney injury (AKI) with a creatinine of 95 µmol/L (baseline 50–60 µmol/L; reference range: 50–98 µmol/L). After 1 L of normal saline, there was significant clinical and biochemical improvement (Table 2). Canagliflozin, metformin, and perindopril were all discontinued on presentation.

Two days into her admission, she developed acute respiratory distress with a respiratory rate of 40 breaths per minute and Kussmaul breathing. A venous blood gas revealed a pH of 7.08 (reference range: 7.35–7.45), partial pressure of carbon dioxide of 17 mmHg (reference range: 40–52 mmHg), and a serum bicarbonate of <8 mmol/L (reference range: 23–29 mmol/L). Additional laboratory tests revealed an anion gap metabolic acidosis with marked ketosis and mildly elevated blood glucose (Table 2). She was diagnosed with euglycemic DKA, secondary to recent SGLT2 inhibitor therapy.

We initiated a continuous intravenous infusion of insulin (Humulin R 0.1 units/kg/h). Given euglycemia and low serum potassium, an intravenous infusion of 5% dextrose with potassium chloride (40 mEq/L) was co-administered. Her acid-base status normalized within 24 h, and she was bridged to subcutaneous long-acting insulin with a two hour overlap before discontinuing intravenous insulin. Five hours after stopping the insulin infusion, laboratory investigations demonstrated a recurrent anion gap metabolic acidosis (Table 2). Intravenous insulin was re instituted and after 24 h of clinical stability, the patient was successfully transitioned to a higher dose of subcutaneous long-acting insulin.

### Table 1

| Medication          | Dosage                       |
|---------------------|------------------------------|
| Canagliflozin       | 100 mg orally daily          |
| Metformin           | 1 g orally twice daily       |
| Acetylsalicylic acid| 81 mg orally daily           |
| Perindopril         | 4 mg orally daily            |
| Rosuvastatin        | 10 mg orally daily           |
| Amlodipine          | 5 mg orally daily            |
| Metoprolol          | 25 mg orally twice daily     |
| Quetiapine          | 12.5 mg orally daily         |
| Cyanocobalamin      | 1000 µg orally daily         |
| Bisacodyl           | 5 mg orally three times per week |
| Multivitamin        | Orally daily                 |
| Cranberry extract   | Orally daily                 |

### Table 2

|                  |                  |                  |                  |
|------------------|------------------|------------------|------------------|
|                  | Day 0: On Presentation | Day 0: After Fluid Resuscitation | Day 2: Clinical Detoxination | Day 3: Transition to Long-acting Insulin | Day 9: After Insulin Dose Reduction | Day 18: After Insulin Cessation |
| Anion Gap        | 18               | 14               | >24              | 10               | 14               | 9                |
| Lactate          | 21               | 21               | <5               | 19               | 19               | 22               |
| Bicarbonate      | 18               | 14               | >24              | 10               | 14               | 9                |
| (5–11 mmol/L)    | 4.7              | 2.0              | 8.0              | 1.1              | 4.0              | 0.9              |
| (0.5–2.2 mmol/L)|                  |                  |                  |                  |                  |                  |
| Serum Glucose    |                  |                  |                  |                  |                  |                  |
| (3.8–7.7 mmol/L)|                  |                  |                  |                  |                  |                  |
| Uric Acid        |                  |                  |                  |                  |                  |                  |
| Creatinine       |                  |                  |                  |                  |                  |                  |
| (50–98 µmol/L)   |                  |                  |                  |                  |                  |                  |
| Serum Ketones    |                  |                  |                  |                  |                  |                  |
| (mmol/L)         |                  |                  |                  |                  |                  |                  |
| Urine Ketones    |                  |                  |                  |                  |                  |                  |
| (mmol/L)         |                  |                  |                  |                  |                  |                  |
| Serum Glucose    |                  |                  |                  |                  |                  |                  |
| (3.8–7.7 mmol/L)|                  |                  |                  |                  |                  |                  |
| Urine Glucose    |                  |                  |                  |                  |                  |                  |
| (mmol/L)         |                  |                  |                  |                  |                  |                  |
| Serum Creatinine |                  |                  |                  |                  |                  |                  |
| (50–98 µmol/L)   |                  |                  |                  |                  |                  |                  |
| Note: Reference ranges (where applicable) and units in brackets. Empty cells indicate laboratory tests that were not obtained.
Urine and serum ketone levels remained elevated for another 9 and 10 days (days 13 and 14 of admission), respectively. Urinalysis continued to show significant glycosuria despite euglycemia. An attempt to decrease the dose of long-acting insulin by 25% on day 9 of admission triggered a relapse of ketoacidosis (Table 2). When urine ketones became negative, a more modest reduction in the dose of long-acting insulin by 2 units (12.5%) was tolerated. After three consecutive days of negative serum ketone measurements and a cumulative 16 days of insulin therapy, long-acting insulin was discontinued without issue. The patient was monitored for another 3 days with no recurrence of ketoacidosis, and she was subsequently discharged home with recommendations to discontinue canagliflozin permanently. Outpatient blood- and urine ketones became negative, a more modest reduction of long-acting insulin by 25% on day 9 of admission.

3 | DISCUSSION

Most cases of SGLT2 inhibitor-associated euglycemic DKA resolve within a few days of treatment. The product monograph of canagliflozin states that the elevation in urinary glucose excretion approaches baseline by approximately 3 days following discontinuation. However, small studies suggest that SGLT2 inhibitor-associated euglycemic DKA may take more than twice as long to resolve as classic DKA. There are several reports of patients who developed euglycemic DKA requiring insulin therapy for 1–2 weeks following SGLT2 inhibitor cessation (Table 3). Classic DKA parameters, such as ketonemia, have been shown to worsen upon insulin dose reductions during euglycemic DKA management, even after normalization of acid-base status (Table 3).

Each SGLT2 inhibitor agent demonstrates distinct pharmacokinetic and pharmacodynamic profiles. Compared with other SGLT2 inhibitors, canagliflozin has the highest lipophilicity. Canagliflozin primarily undergoes phase 2 metabolism (which is generally less susceptible to drug-drug interactions) by uridine diphosphate glycosyltransferase enzymes to inactive metabolites. The half-life of canagliflozin is 10.6 h for a 100 mg dose and 13.1 h for a 300 mg dose, with approximately 33% renally cleared. Unbound drug plasma concentrations may not correlate with pharmacodynamic response as evidenced by significant urinary glucose excretion after SGLT2 inhibitor concentrations are diminished in healthy individuals. Although 8 of 13 cases in our literature review on prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy were associated with canagliflozin use (Table 3), persistent pharmacologic response may be a class-related adverse event. Sustained urinary glucose excretion response has also been described among other SGLT2 inhibitors, including dapagliflozin and empagliflozin.

To the best of our knowledge, the etiology of the disconnection between plasma SGLT2 inhibitor concentration and pharmacodynamic response has yet to be fully explained. A case series form Beth Israel Deaconess Medical Center identified 6 patients with type 1 diabetes mellitus or T2DM who developed SGLT2 inhibitor-associated DKA requiring prolonged intensive care unit courses of 4 or more days. These patients were treated with an intravenous insulin infusion for 41.5–132 h, had glycosuria for 3–10 days after SGLT2 inhibitor cessation, and in three cases, experienced relapse of DKA in hospital. The authors postulated that inadequate insulin administration or carbohydrate restriction, concurrent with ongoing SGLT2 inhibitor-induced glycosuria, predisposed patients to DKA relapse. In addition to the above-mentioned case series, we have summarized similar published cases in Table 3.

While insulin is required to treat euglycemic DKA, insulin deficits alone are insufficient to explain the persistence of SGLT2 inhibitor effects—particularly for patients who did not previously require insulin. The exact mechanism of prolonged ketosis and glycosuria far beyond the standard drug clearance period of five half-lives is unknown, but likely contributing factors are detailed in Table 4. In our patient’s case, urinary glucose excretion was disproportionately elevated for 14 days after canagliflozin was discontinued. Urinary glucose values may be an imprecise measure of drug activity in patients with renal impairment and our patient presented with an acute kidney injury, which may partially explain the reduced renal excretion of the SGLT2 inhibitor. Medication review also revealed no known drug-drug interactions with canagliflozin.

The American Diabetes Association recommends against the routine in-hospital use of SGLT2 inhibitors and recommends these medications be avoided in cases of severe illness, in patients with ketonemia or ketonuria, and during prolonged fasting. Furthermore, the U.S. Food and Drug Administration has advised that SGLT2 inhibitors be stopped at least 3 days before scheduled surgeries (4 days for ertugliflozin) and restarted once risk factors for ketoacidosis are resolved. These guidelines do not acknowledge the potential for the pharmacologic effects of SGLT2 inhibitors to persist for more than the five half-lives of elimination as observed in both surgical and non-surgical settings (Table 3). Furthermore, the delayed presentation and ongoing SGLT2 inhibition 14 days following discontinuation suggests the need for a high level of clinical suspicion for euglycemic DKA throughout the first week of hospitalization, and not only at the time of admission.
### TABLE 3 Cases of prolonged euglycemic diabetic ketoacidosis

| Reference          | Age and gender | SGLT inhibitor | Duration of metabolic recovery | Recurrence of euglycemic DKA | Duration of glycosuria | Measurements                                      |
|--------------------|----------------|----------------|-------------------------------|-----------------------------|------------------------|---------------------------------------------------|
| Miwa et al.        | 45-year-old female | Tofogliflozin | 60 h                          | No                          | 5 days                 | pH and HCO₃, Urine glucose                        |
| Pujara et al.      | 50-year-old female | Dapagliflozin | 9 days                        | Yes                         | 9 days                 | Serum ketones, Anion gap, Urine glucose           |
| Fukuda et al.      | 71-year-old female | Canagliflozin | 6 days                        | No                          | 12 days                | Serum ketones, pH and HCO₃, Urine glucose         |
| Kohil et al.       | 65-year-old male | Canagliflozin | 8 days                        | Yes                         | 8 days                 | Serum ketones, Anion gap, Urine glucose           |
| Kelmenson et al.   | 50-year-old woman | Canagliflozin | Unknown                       | Yes                         | 10 days                | pH, Anion gap, Urine ketones, Urine glucose       |
| Rafey et al.       | 44-year-old male | Canagliflozin | 92 h                          | No                          | N/A                    | Serum ketones, pH and HCO₃                        |
| Rafey et al.       | 59-year-old female | Empagliflozin | 92 h                          | Yes                         | N/A                    | Serum ketones, pH, Anion gap                     |
| Sloan et al.       | 63-year-old male | Canagliflozin | 12 days                       | Yes                         | N/A                    | Serum ketones, pH and HCO₃                        |
| Yehya et al.       | 57-year-old female | Empagliflozin | 9 days                        | Yes                         | 14 days                | Serum ketones, Anion gap, Urine ketones           |
| Mistry et al.      | 47-year-old female | Empagliflozin | 5 days                        | No                          | N/A                    | Serum ketones, pH, Anion gap                     |
| Peters et al.      | 64-year-old female | Canagliflozin | 6 days                        | No                          | N/A                    | Serum ketones, pH, Anion gap                     |
| Adachi et al.      | 27-year-old female | Canagliflozin | 4 days                        | No                          | 5 days                 | Venous pH, Urine glucose                         |
| Maraka et al.      | 51-year-old female | Canagliflozin | 5 days                        | Yes                         | N/A                    | Serum ketones, pH, Anion gap                     |
| Kohil et al.       | 65-year-old male | Canagliflozin | 8 days                        | Yes                         | 8 days                 | Serum ketones, Anion gap, Urine glucose, Urine ketones |

Abbreviations: sodium-glucose cotransporter 2 (SGLT2), diabetic ketoacidosis (DKA), bicarbonate (HCO₃), sodium chloride (NaCl), and uridine diphosphate glucuronosyltransferase (UGT).
| Factors contributing to prolonged effect | Intravenous insulin | Subcutaneous insulin | Other therapies |
|----------------------------------------|---------------------|----------------------|----------------|
| N/A                                    | 0–60; dose increase at 24 h | No                   | Dextrose infusion from 12–96 h |
| Acute kidney injury                    | 2 h on day 1         | Switched to sliding scale Humalog when blood glucose >10 mmol/L on days 1–5 | Dextrose 5% in 0.45 NaCl and 40 mEq KCl at 70 mL/h on days 6–9 |
| Lack of continuous insulin administration early during hospitalization | Restarted on day 6 at 0.8 units/h; increased to 1 unit/h until day 9 | Glargine 10 units daily on day 9 and continued for 8 weeks post-discharge |                         |
| Hypothesized UGT polymorphisms        | No                  | 2 units of short-acting insulin; increased to 6 units/day | Continuous renal replacement therapy from days 2–5 |
| Administration of exogenous insulin   | Drip started after dextrose infusion | Bridge to glargine and continued for 4 months post-discharge | Fluid resuscitation |
| Hypothesized UGT polymorphisms        | Reinstated after recurrence |                         | 9 L dextrose solution |
| Hypothesized transient impairment in β-cell glucose sensing | 1 unit/h and titrated up | Co-administration of basal insulin | Fluid resuscitation |
| Hypothesized stimulation of α-cell glucagon secretion |                         | Discharged on glargine 6 units daily and dulaglutide weekly | |
| Acute Kidney Injury                    | Low dose for initial 28 h | Aspart 9 units three times daily and glargine 22 units daily after hour 92 | Fluid resuscitation |
| Hypothesized stimulation of α-cell glucagon secretion | Restarted from hours 44–92 |                         | |
| Delayed insulin administration         | Alternating fixed (9 units/h) and variable (1–2 units/h) rate infusions for 5 days | Co-administration of basal insulin | Fluid resuscitation |
| Incision and drainage procedures on days 2 and 4 of hospitalization | Initial 12 h | Transitioned to multiple daily injection regime | Dextrose solution |
|                                        | Reinstated from hours 19–67 |                         | |
|                                        | Reinstated from hour 79 to day 9 |                         | |
|                                        | Bridged to glargine 25 units with lispro 1 unit for every 50 mg/dL above 150 mg/dL |                         | |
|                                        | Transitioned back to glargine 30 units with lispro 10 units three times daily and lispro correction scale 1 unit for every 50 mg/dL above 150 mg/dL |                         | |
|                                        | Basal-bolus regimen at 0.7 units/kg total daily dose at discharge |                         | |
| N/A                                    | Drip for 5 days       | Discharged on glargine and lispro | Dextrose drip for 5 days |
| Hypovolemia                            | Drip for 6 days       | No                   | Dextrose drip for 6 days |
| Hypothesized hyperglucagonemia         | Infusion for 3 days   | Switched to multiple daily injections | Isotonic saline for 1 h switched to 5% dextrose |
| Administration of exogenous insulin    |                         |                         | |
| Increase in glomerular filtration rate |                         |                         | |
| Hypothesized delayed reversibility of SGLT2 inhibition |                         |                         | |
| Solitary kidney and acute kidney injury | Yes                | Transitioned to glargine 10 units daily and aspart correction as needed (6 units/day) | Intravenous fluids |
| Hypothesized hyperglucagonemia         | Transitioned back on postoperative day 8 |                         | |
| Hypothesized continued drug binding to renal transport proteins | Initiated on postoperative day 4 | Transitioned back on postoperative day 11 and discharged on a subcutaneous insulin regimen | Sodium bicarbonate ampules and infusion |
|                                        | Restarted on postoperative day 9 |                         | Dextrose-containing fluids |
As the indications for SGLT2 inhibitor therapy expand, the underlying mechanisms of prolonged ketosis and glycosuria merit further study. Possible explanatory factors include a slow off-rate of SGLT2 inhibition, metabolizing enzyme polymorphisms, decreased renal function, and drug lipophilicity. More practically, inpatient physicians should also be aware of the possibility of a prolonged period of insulin dependency in admitted patients who develop euglycemic DKA related to SGLT2 inhibitor use. Furthermore, clinicians should also be aware of the potential for drug effects to persist well beyond five half-lives, the typical period used to guide pre-operative medication recommendations.

ACKNOWLEDGMENT
None.

CONFLICT OF INTEREST
No conflicts of interest.

AUTHOR CONTRIBUTIONS
DB, RK, PW, and LLS contributed to the conception and design of the manuscript. DB, RK, and LLS wrote the initial draft of the manuscript. DB, PW, and LLS edited the draft and reshaped it into this manuscript. All authors approved final version of manuscript and agree to be responsible for all aspects of the work.

ETHICAL APPROVAL
This report did not necessitate formal review and approval from an institutional review board or ethics committee.

CONSENT
The authors have obtained informed consent from the patient for publication.

DATA AVAILABILITY STATEMENT
Data available upon request.

## CONCLUSION

As the indications for SGLT2 inhibitor therapy expand, the underlying mechanisms of prolonged ketosis and glycosuria merit further study. Possible explanatory factors include a slow off-rate of SGLT2 inhibition, metabolizing enzyme polymorphisms, decreased renal function, and drug lipophilicity. More practically, inpatient physicians should be aware of the possibility of a prolonged period of insulin dependency in admitted patients who develop euglycemic DKA related to SGLT2 inhibitor use. Furthermore, clinicians should also be aware of the potential for drug effects to persist well beyond five half-lives, the typical period used to guide pre-operative medication recommendations.

### ACKNOWLEDGMENT
None.

### CONFLICT OF INTEREST
No conflicts of interest.

### AUTHOR CONTRIBUTIONS

*DB, RK, PW, and LLS contributed to the conception and design of the manuscript. DB, RK, and LLS wrote the initial draft of the manuscript. DB, PW, and LLS edited the draft and reshaped it into this manuscript. All authors approved final version of manuscript and agree to be responsible for all aspects of the work.***

### ETHICAL APPROVAL

This report did not necessitate formal review and approval from an institutional review board or ethics committee.

### CONSENT

The authors have obtained informed consent from the patient for publication.

### DATA AVAILABILITY STATEMENT

Data available upon request.

### REFERENCES

1. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. *Diabetes Care*. 2015;38(9):1638-1642. https://doi.org/10.2337/dc15-1380

2. INVOKANA: HIGHLIGHTS OF PRESCRIBING INFORMATION. *US Food and Drug Administration*. 2020. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf

3. Ata F, Yousaf Z, Khan AA, et al. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. *Sci Rep*. 2021;11(1). https://doi.org/10.1038/s41598-021-89752-w

4. Jeon JY, Kim SK, Kim KS, et al. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. *Diabetes Metab*. 2019;45(5):453-457. https://doi.org/10.1016/j.diabet.2019.01.001

5. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? *Diabetes*. 2012;61(9):2199-2204. https://doi.org/10.2337/db12-0052

6. Mayoux E, Liebig S, Martin H, Mark M. Comparison in tissue distribution and selectivity among the three sodium-glucose cotransporter inhibitors empagliflozin, dapagliflozin and canagliflozin. *Clin Pharmacol Drug Dev*. 2017;6(Suppl 1):3-72. https://doi.org/10.1002/cpdd.385

7. Devineni D, Polidori D. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. *Clin Pharmacokinet*. 2015;54(10):1027-1041. https://doi.org/10.1007/s40262-015-0285-z

8. Westcott GP, Segal AR, Mitri J, Brown FM. Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy. *Endocrinol Diabetes Metab*. 2020;3(2):e00117. https://doi.org/10.1002/edm2.117

9. American Diabetes A. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021;44(Suppl 1):S211–S220. https://doi.org/10.2337/dc21-S015

### TABLE 4

| Factors potentially contributing to prolonged SGLT2 inhibitor effect |
|-----------------------------------------------|
| Slow off-rate of SGLT2 inhibition | Prolonged urinary glucose excretion despite low canagliflozin plasma concentrations |
| Metabolizing enzyme polymorphisms | Increased systemic exposure to canagliflozin in patients with genetic polymorphisms in the UGT1A9 and UGT2B4 enzymes |
| Decreased renal function | Increased systemic exposure to canagliflozin |
| | Slightly lengthens the half-life of the drug |
| | Age-associated loss of renal function predisposes to kidney injury, which extend beyond changes in glomerular filtration rate |
| Drug lipophilicity | Increased adiposity in older adults expands the volume of distribution |
| | Potential increase in the elimination half-life of canagliflozin |

### ORCID

- David Bobrowski [https://orcid.org/0000-0001-6270-7042](https://orcid.org/0000-0001-6270-7042)
- Lauren Lapointe-Shaw [https://orcid.org/0000-0003-4485-6719](https://orcid.org/0000-0003-4485-6719)
10. Miwa M, Nakajima M, Kaszynski RH, Goto H. Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium–glucose cotransporter 2 inhibitor. BMJ Case Rep. 2020;13(10):e235969. https://doi.org/10.1136/bcr-2020-235969

11. Pujara S, Ioachimescu A. Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. J Investig Med High Impact Case Rep. 2017;5(2):232470961771004. https://doi.org/10.1177/2324709617710040

12. Fukuda M, Nabeta M, Muta T, Fukami K, Takasu O. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report. International J Emerg Med. 2020;13(1):2. https://doi.org/10.1186/s12245-020-0261-8

13. Kelmenson DA, Burr K, Azhar Y, Reynolds P, Baker CA, Rasouli N. Euglycemic diabetic ketoacidosis with prolonged glucosuria associated with the sodium-glucose cotransporter-2 canagliflozin. J Investig Med High Impact Case Rep. 2017;5(2):232470961771273. https://doi.org/10.1177/2324709617712736

14. Rafey MF, Butt A, Coffey B, et al. Prolonged acidosis is a feature of SGLT2i-induced euglycemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep. 2019;2019. https://doi.org/10.1530/EDM-19-0087

15. Sloan G, Kakoudaki T, Ranjan N. Prolonged diabetic ketoacidosis associated with canagliflozin. Endocrinol Diabetes Metab Case Rep. 2018;2018. https://doi.org/10.1530/EDM-17-0177

16. Yehya A, Sadhu A. Sodium-glucose cotransporter 2 inhibitor-associated prolonged euglycemic diabetic ketoacidosis in type 2 diabetes: a case report and literature review. Clin Diabetes. 2020;38(1):112-116. https://doi.org/10.2337/cd19-0035

17. Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: A case series and review of literature. AACE Clin Case Rep. 2021;7(1):17-19. https://doi.org/10.1016/j.jaace.2020.11.009

18. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693. https://doi.org/10.2337/dc15-0843

19. Adachi J, Inaba Y, Maki C. Euglycemic diabetic ketoacidosis with persistent diuresis treated with canagliflozin. Intern Med. 2017;56(2):187-190. https://doi.org/10.2169/internalmedicine.56.7501

20. Maraka S, Kearns AE, Kittah NE, O’Keeffe DT. Recurrent euglycemic diabetic ketoacidosis after discontinuation of sodium-glucose cotransporter 2 inhibitor. Diabetes Res Clin Pract. 2016;118:77-78. https://doi.org/10.1016/j.diabres.2016.06.004

21. Kohli J, Goldfarb S. Quiz: Metabolic acidosis in a patient with type 2 diabetes. Am J Kidney Dis. 2017;69(6):A11-A13. https://doi.org/10.1053/j.ajkd.2017.02.369

22. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061-1072. https://doi.org/10.1002/jcph.506

23. Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis. 2010;17(4):302-307. https://doi.org/10.1053/j.ackd.2010.05.002

How to cite this article: Bobrowski D, Kumar R, Wu PE, Lapointe-Shaw L. Prolonged ketosis and glucosuria secondary to SGLT2 inhibitor therapy. Clin Case Rep. 2021;9:e05057. https://doi.org/10.1002/ccr3.5057